[{"orgOrder":0,"company":"Hopstem Biotechnology","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"hNPC01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Hopstem Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hopstem Biotechnology \/ Lilly Asia Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Hopstem Biotechnology \/ Lilly Asia Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Hopstem Biotechnology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : The financing will be used to support the IND application of hNPC01 (with stroke as the first indication) both in China and the United States, the following clinical trial, expansion of product pipelines, and development of automated closed-system manufa...

                          Product Name : hNPC01

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 31, 2021

                          Lead Product(s) : hNPC01

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Lilly Asia Ventures

                          Deal Size : $40.0 million

                          Deal Type : Series B Financing

                          blank